Difference between revisions of "Malignant pleural mesothelioma"
m (Text replacement - "<span style="background:#00CD00; padding:3px 6px 3px 6px; border-color:black; border-width:2px; border-style:solid;">Phase III</span>" to "style="background-color:#00CD00"|Phase III") |
m |
||
Line 22: | Line 22: | ||
|[[Levels_of_Evidence#Evidence|'''Evidence''']] | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
|'''Comparator''' | |'''Comparator''' | ||
+ | |[[Levels_of_Evidence#Efficacy|'''Efficacy''']] | ||
|- | |- | ||
− | |[ | + | |rowspan=2|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2431123 Muers et al. (MS01)] |
− | |style="background-color:#00CD00"|Phase III | + | |rowspan=2 style="background-color:#00CD00"|Phase III |
− | |[[Mesothelioma#MVP|MVP]] | + | |[[Mesothelioma#MVP|MVP]] |
+ | |style="background-color:#eeee00"|Seems not superior | ||
+ | |- | ||
+ | |[[Mesothelioma#Vinorelbine_.28Navelbine.29|Vinorelbine]] | ||
+ | |style="background-color:#ff0000"|Might have inferior OS | ||
|- | |- | ||
|} | |} | ||
Line 32: | Line 37: | ||
===References=== | ===References=== | ||
− | # Muers MF, Stephens RJ, Fisher P, Darlison L, Higgs CM, Lowry E, Nicholson AG, O'Brien M, Peake M, Rudd R, Snee M, Steele J, Girling DJ, Nankivell M, Pugh C, Parmar MK; MS01 Trial Management Group. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet. 2008 May 17;371(9625):1685-94. [ | + | # Muers MF, Stephens RJ, Fisher P, Darlison L, Higgs CM, Lowry E, Nicholson AG, O'Brien M, Peake M, Rudd R, Snee M, Steele J, Girling DJ, Nankivell M, Pugh C, Parmar MK; MS01 Trial Management Group. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet. 2008 May 17;371(9625):1685-94. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2431123 link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18486741 PubMed] |
==Carboplatin & Pemetrexed {{#subobject:2feba8|Regimen=1}}== | ==Carboplatin & Pemetrexed {{#subobject:2feba8|Regimen=1}}== | ||
Line 68: | Line 73: | ||
===References=== | ===References=== | ||
− | # Ceresoli GL, Zucali PA, Favaretto AG, Grossi F, Bidoli P, Del Conte G, Ceribelli A, Bearz A, Morenghi E, Cavina R, Marangolo M, Parra HJ, Santoro A. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol. 2006 Mar 20;24(9):1443-8. [http://jco.ascopubs.org/content/24/9/1443.long link to original article] '''contains verified protocol''' [ | + | # Ceresoli GL, Zucali PA, Favaretto AG, Grossi F, Bidoli P, Del Conte G, Ceribelli A, Bearz A, Morenghi E, Cavina R, Marangolo M, Parra HJ, Santoro A. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol. 2006 Mar 20;24(9):1443-8. [http://jco.ascopubs.org/content/24/9/1443.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16549838 PubMed] |
− | # Castagneto B, Botta M, Aitini E, Spigno F, Degiovanni D, Alabiso O, Serra M, Muzio A, Carbone R, Buosi R, Galbusera V, Piccolini E, Giaretto L, Rebella L, Mencoboni M. Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM). Ann Oncol. 2008 Feb;19(2):370-3. Epub 2007 Dec 20. [http://annonc.oxfordjournals.org/content/19/2/370.long link to original article] '''contains verified protocol''' [ | + | # Castagneto B, Botta M, Aitini E, Spigno F, Degiovanni D, Alabiso O, Serra M, Muzio A, Carbone R, Buosi R, Galbusera V, Piccolini E, Giaretto L, Rebella L, Mencoboni M. Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM). Ann Oncol. 2008 Feb;19(2):370-3. Epub 2007 Dec 20. [http://annonc.oxfordjournals.org/content/19/2/370.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18156144 PubMed] |
==Cisplatin (Platinol) {{#subobject:82fdeb|Regimen=1}}== | ==Cisplatin (Platinol) {{#subobject:82fdeb|Regimen=1}}== | ||
Line 81: | Line 86: | ||
|[[Levels_of_Evidence#Evidence|'''Evidence''']] | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
|'''Comparator''' | |'''Comparator''' | ||
+ | |[[Levels_of_Evidence#Efficacy|'''Efficacy''']] | ||
|- | |- | ||
|[http://jco.ascopubs.org/content/21/14/2636.long Vogelzang et al. 2003] | |[http://jco.ascopubs.org/content/21/14/2636.long Vogelzang et al. 2003] | ||
|style="background-color:#00CD00"|Phase III | |style="background-color:#00CD00"|Phase III | ||
|[[Mesothelioma#Cisplatin_.26_Pemetrexed|Cisplatin & Pemetrexed]] | |[[Mesothelioma#Cisplatin_.26_Pemetrexed|Cisplatin & Pemetrexed]] | ||
+ | |style="background-color:#ff0000"|Seems to have inferior OS | ||
|- | |- | ||
|} | |} | ||
Line 93: | Line 100: | ||
===References=== | ===References=== | ||
− | # Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003 Jul 15;21(14):2636-44. [http://jco.ascopubs.org/content/21/14/2636.long link to original article] '''contains verified protocol''' [ | + | # Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003 Jul 15;21(14):2636-44. [http://jco.ascopubs.org/content/21/14/2636.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12860938 PubMed] |
− | ## '''Update:''' Manegold C, Symanowski J, Gatzemeier U, Reck M, von Pawel J, Kortsik C, Nackaerts K, Lianes P, Vogelzang NJ. Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. Ann Oncol. 2005 Jun;16(6):923-7. Epub 2005 Apr 11. [http://annonc.oxfordjournals.org/content/16/6/923.long link to original article] [ | + | ## '''Update:''' Manegold C, Symanowski J, Gatzemeier U, Reck M, von Pawel J, Kortsik C, Nackaerts K, Lianes P, Vogelzang NJ. Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. Ann Oncol. 2005 Jun;16(6):923-7. Epub 2005 Apr 11. [http://annonc.oxfordjournals.org/content/16/6/923.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/15824080 PubMed] |
==Cisplatin & Gemcitabine {{#subobject:9e4c22|Regimen=1}}== | ==Cisplatin & Gemcitabine {{#subobject:9e4c22|Regimen=1}}== | ||
Line 141: | Line 148: | ||
===References=== | ===References=== | ||
− | # van Haarst JM, Baas P, Manegold Ch, Schouwink JH, Burgers JA, de Bruin HG, Mooi WJ, van Klaveren RJ, de Jonge MJ, van Meerbeeck JP. Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma. Br J Cancer. 2002 Feb 1;86(3):342-5. [http://www.nature.com/bjc/journal/v86/n3/full/6600118a.html link to original article] '''contains verified protocol''' [ | + | # van Haarst JM, Baas P, Manegold Ch, Schouwink JH, Burgers JA, de Bruin HG, Mooi WJ, van Klaveren RJ, de Jonge MJ, van Meerbeeck JP. Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma. Br J Cancer. 2002 Feb 1;86(3):342-5. [http://www.nature.com/bjc/journal/v86/n3/full/6600118a.html link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11875695 PubMed] content property of [http://hemonc.org HemOnc.org] |
− | # Nowak AK, Byrne MJ, Williamson R, Ryan G, Segal A, Fielding D, Mitchell P, Musk AW, Robinson BW. A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer. 2002 Aug 27;87(5):491-6. [http://www.nature.com/bjc/journal/v87/n5/full/6600505a.html link to original article] '''contains verified protocol''' [ | + | # Nowak AK, Byrne MJ, Williamson R, Ryan G, Segal A, Fielding D, Mitchell P, Musk AW, Robinson BW. A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer. 2002 Aug 27;87(5):491-6. [http://www.nature.com/bjc/journal/v87/n5/full/6600505a.html link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12189542 PubMed] |
==Cisplatin & Pemetrexed {{#subobject:c2805d|Regimen=1}}== | ==Cisplatin & Pemetrexed {{#subobject:c2805d|Regimen=1}}== | ||
Line 159: | Line 166: | ||
|style="background-color:#00cd00"|Phase III | |style="background-color:#00cd00"|Phase III | ||
|[[Mesothelioma#Cisplatin_.28Platinol.29|Cisplatin]] | |[[Mesothelioma#Cisplatin_.28Platinol.29|Cisplatin]] | ||
− | | | + | |style="background-color:#00cd00"|Seems to have superior OS |
|- | |- | ||
|[http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)01238-6/abstract Zalcman et al. 2016 (MAPS)] | |[http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)01238-6/abstract Zalcman et al. 2016 (MAPS)] | ||
Line 179: | Line 186: | ||
===References=== | ===References=== | ||
− | # Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003 Jul 15;21(14):2636-44. [http://jco.ascopubs.org/content/21/14/2636.long link to original article] '''contains verified protocol''' [ | + | # Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003 Jul 15;21(14):2636-44. [http://jco.ascopubs.org/content/21/14/2636.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12860938 PubMed] |
− | ## '''Update:''' Manegold C, Symanowski J, Gatzemeier U, Reck M, von Pawel J, Kortsik C, Nackaerts K, Lianes P, Vogelzang NJ. Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. Ann Oncol. 2005 Jun;16(6):923-7. Epub 2005 Apr 11. [http://annonc.oxfordjournals.org/content/16/6/923.long link to original article] [ | + | ## '''Update:''' Manegold C, Symanowski J, Gatzemeier U, Reck M, von Pawel J, Kortsik C, Nackaerts K, Lianes P, Vogelzang NJ. Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. Ann Oncol. 2005 Jun;16(6):923-7. Epub 2005 Apr 11. [http://annonc.oxfordjournals.org/content/16/6/923.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/15824080 PubMed] |
<!-- # '''Abstract:''' Gerard Zalcman, Julien Mazières, Jacques Margery, Laurent Greillier, Clarisse Audigier-Valette, Denis Moro-Sibilot, Oliver Molinier, Romain Corre, Isabelle Monnet, Valérie Gounant, Henri Janicot, Radj Gervais, Chrystele Locher, Bernard Milleron, Quan Tran, Marie Paule Lebitasy, Franck Morin, Christian Creveuil, Jean-Jacques Parienti, Arnaud Scherpereel, French Cooperative Thoracic Intergroup (IFCT). Bevacizumab 15mg/kg plus cisplatin-pemetrexed (CP) triplet versus CP doublet in Malignant Pleural Mesothelioma (MPM): Results of the IFCT-GFPC-0701 MAPS randomized phase 3 trial. J Clin Oncol 33, 2015 (suppl; abstr 7500) [http://meetinglibrary.asco.org/content/150191-156 link to abstract] --> | <!-- # '''Abstract:''' Gerard Zalcman, Julien Mazières, Jacques Margery, Laurent Greillier, Clarisse Audigier-Valette, Denis Moro-Sibilot, Oliver Molinier, Romain Corre, Isabelle Monnet, Valérie Gounant, Henri Janicot, Radj Gervais, Chrystele Locher, Bernard Milleron, Quan Tran, Marie Paule Lebitasy, Franck Morin, Christian Creveuil, Jean-Jacques Parienti, Arnaud Scherpereel, French Cooperative Thoracic Intergroup (IFCT). Bevacizumab 15mg/kg plus cisplatin-pemetrexed (CP) triplet versus CP doublet in Malignant Pleural Mesothelioma (MPM): Results of the IFCT-GFPC-0701 MAPS randomized phase 3 trial. J Clin Oncol 33, 2015 (suppl; abstr 7500) [http://meetinglibrary.asco.org/content/150191-156 link to abstract] --> | ||
− | # Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, Rivière F, Janicot H, Gervais R, Locher C, Milleron B, Tran Q, Lebitasy MP, Morin F, Creveuil C, Parienti JJ, Scherpereel A; French Cooperative Thoracic Intergroup (IFCT). Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016 Apr 2;387(10026):1405-14. Epub 2015 Dec 21. Erratum in: Lancet. 2016 Apr 2;387(10026):e24. [http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)01238-6/abstract link to original article] '''contains protocol''' [ | + | # Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, Rivière F, Janicot H, Gervais R, Locher C, Milleron B, Tran Q, Lebitasy MP, Morin F, Creveuil C, Parienti JJ, Scherpereel A; French Cooperative Thoracic Intergroup (IFCT). Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016 Apr 2;387(10026):1405-14. Epub 2015 Dec 21. Erratum in: Lancet. 2016 Apr 2;387(10026):e24. [http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)01238-6/abstract link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26719230 PubMed] |
==MVP {{#subobject:12f846|Regimen=1}}== | ==MVP {{#subobject:12f846|Regimen=1}}== | ||
Line 196: | Line 203: | ||
|[[Levels_of_Evidence#Evidence|'''Evidence''']] | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
|'''Comparator''' | |'''Comparator''' | ||
+ | |[[Levels_of_Evidence#Efficacy|'''Efficacy''']] | ||
|- | |- | ||
− | |[ | + | |rowspan=2|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2431123 Muers et al. (MS01)] |
− | |style="background-color:#00CD00"|Phase III | + | |rowspan=2 style="background-color:#00CD00"|Phase III |
− | |[[Mesothelioma#Active_symptom_control|Active symptom control]] | + | |[[Mesothelioma#Active_symptom_control|Active symptom control]] |
+ | |style="background-color:#eeee00"|Seems not superior | ||
+ | |- | ||
+ | |[[Mesothelioma#Vinorelbine_.28Navelbine.29|Vinorelbine]] | ||
+ | |style="background-color:#eeee00"|Seems not superior | ||
|- | |- | ||
|} | |} | ||
Line 206: | Line 218: | ||
===References=== | ===References=== | ||
− | # Muers MF, Stephens RJ, Fisher P, Darlison L, Higgs CM, Lowry E, Nicholson AG, O'Brien M, Peake M, Rudd R, Snee M, Steele J, Girling DJ, Nankivell M, Pugh C, Parmar MK; MS01 Trial Management Group. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet. 2008 May 17;371(9625):1685-94. [ | + | # Muers MF, Stephens RJ, Fisher P, Darlison L, Higgs CM, Lowry E, Nicholson AG, O'Brien M, Peake M, Rudd R, Snee M, Steele J, Girling DJ, Nankivell M, Pugh C, Parmar MK; MS01 Trial Management Group. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet. 2008 May 17;371(9625):1685-94. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2431123 link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/18486741 PubMed] |
==PCB {{#subobject:f3f261|Regimen=1}}== | ==PCB {{#subobject:f3f261|Regimen=1}}== | ||
Line 236: | Line 248: | ||
===References=== | ===References=== | ||
<!-- # '''Abstract:''' Gerard Zalcman, Julien Mazières, Jacques Margery, Laurent Greillier, Clarisse Audigier-Valette, Denis Moro-Sibilot, Oliver Molinier, Romain Corre, Isabelle Monnet, Valérie Gounant, Henri Janicot, Radj Gervais, Chrystele Locher, Bernard Milleron, Quan Tran, Marie Paule Lebitasy, Franck Morin, Christian Creveuil, Jean-Jacques Parienti, Arnaud Scherpereel, French Cooperative Thoracic Intergroup (IFCT). Bevacizumab 15mg/kg plus cisplatin-pemetrexed (CP) triplet versus CP doublet in Malignant Pleural Mesothelioma (MPM): Results of the IFCT-GFPC-0701 MAPS randomized phase 3 trial. J Clin Oncol 33, 2015 (suppl; abstr 7500) [http://meetinglibrary.asco.org/content/150191-156 link to abstract] --> | <!-- # '''Abstract:''' Gerard Zalcman, Julien Mazières, Jacques Margery, Laurent Greillier, Clarisse Audigier-Valette, Denis Moro-Sibilot, Oliver Molinier, Romain Corre, Isabelle Monnet, Valérie Gounant, Henri Janicot, Radj Gervais, Chrystele Locher, Bernard Milleron, Quan Tran, Marie Paule Lebitasy, Franck Morin, Christian Creveuil, Jean-Jacques Parienti, Arnaud Scherpereel, French Cooperative Thoracic Intergroup (IFCT). Bevacizumab 15mg/kg plus cisplatin-pemetrexed (CP) triplet versus CP doublet in Malignant Pleural Mesothelioma (MPM): Results of the IFCT-GFPC-0701 MAPS randomized phase 3 trial. J Clin Oncol 33, 2015 (suppl; abstr 7500) [http://meetinglibrary.asco.org/content/150191-156 link to abstract] --> | ||
− | # Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, Rivière F, Janicot H, Gervais R, Locher C, Milleron B, Tran Q, Lebitasy MP, Morin F, Creveuil C, Parienti JJ, Scherpereel A; French Cooperative Thoracic Intergroup (IFCT). Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016 Apr 2;387(10026):1405-14. Epub 2015 Dec 21. Erratum in: Lancet. 2016 Apr 2;387(10026):e24. [http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)01238-6/abstract link to original article] '''contains protocol''' [ | + | # Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, Rivière F, Janicot H, Gervais R, Locher C, Milleron B, Tran Q, Lebitasy MP, Morin F, Creveuil C, Parienti JJ, Scherpereel A; French Cooperative Thoracic Intergroup (IFCT). Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016 Apr 2;387(10026):1405-14. Epub 2015 Dec 21. Erratum in: Lancet. 2016 Apr 2;387(10026):e24. [http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)01238-6/abstract link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26719230 PubMed] |
==Pemetrexed (Alimta) {{#subobject:d9af60|Regimen=1}}== | ==Pemetrexed (Alimta) {{#subobject:d9af60|Regimen=1}}== | ||
Line 263: | Line 275: | ||
===References=== | ===References=== | ||
− | # Taylor P, Castagneto B, Dark G, Marangolo M, Scagliotti GV, van Klaveren RJ, Labianca R, Serke M, Schuette W, van Meerbeeck JP, Heigener D, Liu Y, Adachi S, Blatter J, von Pawel J. Single-agent pemetrexed for chemonaïve and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program. J Thorac Oncol. 2008 Jul;3(7):764-71. [http://journals.lww.com/jto/Fulltext/2008/07000/Single_Agent_Pemetrexed_for_Chemonaive_and.12.aspx link to original article] '''contains verified protocol''' [ | + | # Taylor P, Castagneto B, Dark G, Marangolo M, Scagliotti GV, van Klaveren RJ, Labianca R, Serke M, Schuette W, van Meerbeeck JP, Heigener D, Liu Y, Adachi S, Blatter J, von Pawel J. Single-agent pemetrexed for chemonaïve and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program. J Thorac Oncol. 2008 Jul;3(7):764-71. [http://journals.lww.com/jto/Fulltext/2008/07000/Single_Agent_Pemetrexed_for_Chemonaive_and.12.aspx link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18594323 PubMed] |
==Vinorelbine (Navelbine) {{#subobject:9ec507|Regimen=1}}== | ==Vinorelbine (Navelbine) {{#subobject:9ec507|Regimen=1}}== | ||
Line 275: | Line 287: | ||
|[[Levels_of_Evidence#Evidence|'''Evidence''']] | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
|'''Comparator''' | |'''Comparator''' | ||
+ | |[[Levels_of_Evidence#Efficacy|'''Efficacy''']] | ||
+ | |- | ||
+ | |rowspan=2|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2431123 Muers et al. (MS01)] | ||
+ | |rowspan=2 style="background-color:#00CD00"|Phase III | ||
+ | |[[Mesothelioma#Active_symptom_control|Active symptom control]] | ||
+ | |style="background-color:#00CD00"|Might have superior OS | ||
|- | |- | ||
− | |[ | + | |[[Mesothelioma#MVP|MVP]] |
− | |style="background-color:# | + | |style="background-color:#eeee00"|Seems not superior |
− | |||
|- | |- | ||
|} | |} | ||
Line 289: | Line 306: | ||
===References=== | ===References=== | ||
− | # Muers MF, Stephens RJ, Fisher P, Darlison L, Higgs CM, Lowry E, Nicholson AG, O'Brien M, Peake M, Rudd R, Snee M, Steele J, Girling DJ, Nankivell M, Pugh C, Parmar MK; MS01 Trial Management Group. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet. 2008 May 17;371(9625):1685-94. [ | + | # Muers MF, Stephens RJ, Fisher P, Darlison L, Higgs CM, Lowry E, Nicholson AG, O'Brien M, Peake M, Rudd R, Snee M, Steele J, Girling DJ, Nankivell M, Pugh C, Parmar MK; MS01 Trial Management Group. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet. 2008 May 17;371(9625):1685-94. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2431123 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18486741 PubMed] |
=Second-line therapy= | =Second-line therapy= | ||
Line 302: | Line 319: | ||
|[[Levels_of_Evidence#Evidence|'''Evidence''']] | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
|'''Comparator''' | |'''Comparator''' | ||
+ | |[[Levels_of_Evidence#Efficacy|'''Efficacy''']] | ||
|- | |- | ||
|[http://jco.ascopubs.org/content/26/10/1698.long Jassem et al. 2008] | |[http://jco.ascopubs.org/content/26/10/1698.long Jassem et al. 2008] | ||
|style="background-color:#00CD00"|Phase III | |style="background-color:#00CD00"|Phase III | ||
|[[Mesothelioma#Pemetrexed_.28Alimta.29_2|Pemetrexed]] | |[[Mesothelioma#Pemetrexed_.28Alimta.29_2|Pemetrexed]] | ||
+ | |style="background-color:#ff0000"|Seems to have inferior PFS | ||
|- | |- | ||
|} | |} | ||
Line 312: | Line 331: | ||
===References=== | ===References=== | ||
− | # Jassem J, Ramlau R, Santoro A, Schuette W, Chemaissani A, Hong S, Blatter J, Adachi S, Hanauske A, Manegold C. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol. 2008 Apr 1;26(10):1698-704. [http://jco.ascopubs.org/content/26/10/1698.long link to original article] '''contains verified protocol''' [ | + | # Jassem J, Ramlau R, Santoro A, Schuette W, Chemaissani A, Hong S, Blatter J, Adachi S, Hanauske A, Manegold C. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol. 2008 Apr 1;26(10):1698-704. [http://jco.ascopubs.org/content/26/10/1698.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18375898 PubMed] |
==Gemcitabine (Gemzar)== | ==Gemcitabine (Gemzar)== | ||
Line 322: | Line 341: | ||
===References=== | ===References=== | ||
− | # Manegold C, Symanowski J, Gatzemeier U, Reck M, von Pawel J, Kortsik C, Nackaerts K, Lianes P, Vogelzang NJ. Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. Ann Oncol. 2005 Jun;16(6):923-7. Epub 2005 Apr 11. [http://annonc.oxfordjournals.org/content/16/6/923.long link to original article] [ | + | # Manegold C, Symanowski J, Gatzemeier U, Reck M, von Pawel J, Kortsik C, Nackaerts K, Lianes P, Vogelzang NJ. Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. Ann Oncol. 2005 Jun;16(6):923-7. Epub 2005 Apr 11. [http://annonc.oxfordjournals.org/content/16/6/923.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/15824080 PubMed] |
==Pemetrexed (Alimta) {{#subobject:7b23e|Regimen=1}}== | ==Pemetrexed (Alimta) {{#subobject:7b23e|Regimen=1}}== | ||
Line 334: | Line 353: | ||
|[[Levels_of_Evidence#Evidence|'''Evidence''']] | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
|'''Comparator''' | |'''Comparator''' | ||
+ | |[[Levels_of_Evidence#Efficacy|'''Efficacy''']] | ||
|- | |- | ||
|[http://jco.ascopubs.org/content/26/10/1698.long Jassem et al. 2008] | |[http://jco.ascopubs.org/content/26/10/1698.long Jassem et al. 2008] | ||
|style="background-color:#00CD00"|Phase III | |style="background-color:#00CD00"|Phase III | ||
|[[Mesothelioma#Best_supportive_care|Best supportive care]] | |[[Mesothelioma#Best_supportive_care|Best supportive care]] | ||
+ | |style="background-color:#00CD00"|Seems to have superior PFS | ||
|- | |- | ||
|} | |} | ||
Line 351: | Line 372: | ||
===References=== | ===References=== | ||
− | # Jassem J, Ramlau R, Santoro A, Schuette W, Chemaissani A, Hong S, Blatter J, Adachi S, Hanauske A, Manegold C. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol. 2008 Apr 1;26(10):1698-704. [http://jco.ascopubs.org/content/26/10/1698.long link to original article] '''contains verified protocol''' [ | + | # Jassem J, Ramlau R, Santoro A, Schuette W, Chemaissani A, Hong S, Blatter J, Adachi S, Hanauske A, Manegold C. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol. 2008 Apr 1;26(10):1698-704. [http://jco.ascopubs.org/content/26/10/1698.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18375898 PubMed] |
==Vinorelbine (Navelbine) {{#subobject:4e5cff|Regimen=1}}== | ==Vinorelbine (Navelbine) {{#subobject:4e5cff|Regimen=1}}== | ||
Line 373: | Line 394: | ||
===References=== | ===References=== | ||
− | # Stebbing J, Powles T, McPherson K, Shamash J, Wells P, Sheaff MT, Slater S, Rudd RM, Fennell D, Steele JP. The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma. Lung Cancer. 2009 Jan;63(1):94-7. Epub 2008 May 16. [http://www.lungcancerjournal.info/article/S0169-5002%2808%2900194-3/abstract link to original article] '''contains verified protocol''' [ | + | # Stebbing J, Powles T, McPherson K, Shamash J, Wells P, Sheaff MT, Slater S, Rudd RM, Fennell D, Steele JP. The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma. Lung Cancer. 2009 Jan;63(1):94-7. Epub 2008 May 16. [http://www.lungcancerjournal.info/article/S0169-5002%2808%2900194-3/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18486273 PubMed] |
+ | |||
+ | =Patient resources= | ||
+ | *[https://www.treatmesothelioma.org/ TreatMesothelioma.org] - "a Mesothelioma Treatment Community" with education information for patients about mesothelioma and treatment | ||
[[Category:Chemotherapy regimens]] | [[Category:Chemotherapy regimens]] | ||
[[Category:Solid oncology regimens]] | [[Category:Solid oncology regimens]] | ||
− | |||
− | |||
− |
Revision as of 02:18, 21 November 2016
Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.
Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.
19 regimens on this page
32 variants on this page
|
First-line therapy
Active symptom control
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
Muers et al. (MS01) | Phase III | MVP | Seems not superior |
Vinorelbine | Might have inferior OS |
No antineoplastic treatment; used as a comparator arm and here for reference purposes only.
References
- Muers MF, Stephens RJ, Fisher P, Darlison L, Higgs CM, Lowry E, Nicholson AG, O'Brien M, Peake M, Rudd R, Snee M, Steele J, Girling DJ, Nankivell M, Pugh C, Parmar MK; MS01 Trial Management Group. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet. 2008 May 17;371(9625):1685-94. link to PMC article contains verified protocol PubMed
Carboplatin & Pemetrexed
back to top |
Regimen
Study | Evidence |
Ceresoli et al. 2006 | Phase II |
Castagneto et al. 2007 | Phase II |
Chemotherapy
- Carboplatin (Paraplatin) AUC 5 IV over 30 minutes once on day 1, given second, 30 minutes after pemetrexed
- Pemetrexed (Alimta) 500 mg/m2 IV over 10 minutes once on day 1, given first
Supportive medications
- (varies depending on reference):
- Folic acid 350 to 600 mcg PO once per day, starting at least 1 week before Pemetrexed (Alimta), to continue throughout therapy
- Cyanocobalamin (Vitamin B12) 1000 mcg IM once at least 1 week before Pemetrexed (Alimta), then 1000 mcg to be given every 9 weeks thereafter
- Dexamethasone (Decadron) 4 mg PO BID the day before, the day of, and day after Pemetrexed (Alimta)
- Alternatively, Dexamethasone (Decadron) may be given 8 mg IM the day before, the day of, and day after Pemetrexed (Alimta)
- No NSAIDs (nonsteroidal anti-inflammatory drugs) for 2 days (5 days for NSAIDs with longer half-lives) before or after Pemetrexed (Alimta)
21-day cycles
Up to 9 cycles in Castagneto et al. 2007.
References
- Ceresoli GL, Zucali PA, Favaretto AG, Grossi F, Bidoli P, Del Conte G, Ceribelli A, Bearz A, Morenghi E, Cavina R, Marangolo M, Parra HJ, Santoro A. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol. 2006 Mar 20;24(9):1443-8. link to original article contains verified protocol PubMed
- Castagneto B, Botta M, Aitini E, Spigno F, Degiovanni D, Alabiso O, Serra M, Muzio A, Carbone R, Buosi R, Galbusera V, Piccolini E, Giaretto L, Rebella L, Mencoboni M. Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM). Ann Oncol. 2008 Feb;19(2):370-3. Epub 2007 Dec 20. link to original article contains verified protocol PubMed
Cisplatin (Platinol)
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
Vogelzang et al. 2003 | Phase III | Cisplatin & Pemetrexed | Seems to have inferior OS |
Chemotherapy
- Cisplatin (Platinol) 75 mg/m2 IV over 2 hours once on day 1
21-day cycles
References
- Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003 Jul 15;21(14):2636-44. link to original article contains verified protocol PubMed
- Update: Manegold C, Symanowski J, Gatzemeier U, Reck M, von Pawel J, Kortsik C, Nackaerts K, Lianes P, Vogelzang NJ. Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. Ann Oncol. 2005 Jun;16(6):923-7. Epub 2005 Apr 11. link to original article PubMed
Cisplatin & Gemcitabine
back to top |
Regimen #1
Study | Evidence |
Nowak et al. 2002 | Phase II |
Chemotherapy
- Cisplatin (Platinol) 100 mg/m2 IV over 1 hour once on day 1, given first
- Gemcitabine (Gemzar) 1000 mg/m2 IV over 30 minutes once per day on days 1, 8, 15, given second
Supportive medications
- Minimum of 3 liters of IV hydration for Cisplatin (Platinol), with magnesium supplementation
- 5HT-3 antagonists & Dexamethasone (Decadron) IV once per day on days 1, 8, 15 before chemotherapy
- 5HT-3 antagonists, Dexamethasone (Decadron), and/or phenothiazines for antiemesis PO or by rectal suppository for 3 to 5 days after Cisplatin (Platinol)
28-day cycle for up to 6 cycles
Regimen #2
Study | Evidence |
van Haarst et al. 2002 | Phase II |
Chemotherapy
- Cisplatin (Platinol) 80 mg/m2 IV over 3 hours once on day 1, given second
- Gemcitabine (Gemzar) 1250 mg/m2 IV over 30 minutes once per day on days 1 & 8, given first
Supportive medications
- Minimum of 2 liters of IV hydration for Cisplatin (Platinol)
- 5HT-3 antagonists & corticosteroids before Cisplatin (Platinol)
21-day cycle for up to 6 cycles
References
- van Haarst JM, Baas P, Manegold Ch, Schouwink JH, Burgers JA, de Bruin HG, Mooi WJ, van Klaveren RJ, de Jonge MJ, van Meerbeeck JP. Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma. Br J Cancer. 2002 Feb 1;86(3):342-5. link to original article contains verified protocol PubMed content property of HemOnc.org
- Nowak AK, Byrne MJ, Williamson R, Ryan G, Segal A, Fielding D, Mitchell P, Musk AW, Robinson BW. A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer. 2002 Aug 27;87(5):491-6. link to original article contains verified protocol PubMed
Cisplatin & Pemetrexed
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
Vogelzang et al. 2003 | Phase III | Cisplatin | Seems to have superior OS |
Zalcman et al. 2016 (MAPS) | Phase III | PCB | Seems to have inferior OS |
Chemotherapy
- Cisplatin (Platinol) 75 mg/m2 IV over 2 hours once on day 1, given second, 30 minutes after pemetrexed
- Pemetrexed (Alimta) 500 mg/m2 IV over 10 minutes once on day 1, given first
Supportive medications
- Folic acid 350 to 1000 mcg PO once per day, starting 1 to 3 weeks before Pemetrexed (Alimta), to continue throughout therapy
- Cyanocobalamin (Vitamin B12) 1000 mcg IM once 1 to 3 weeks before Pemetrexed (Alimta), then 1000 mcg to be given every 9 weeks thereafter
- Dexamethasone (Decadron) (dose not specified by reference) the day before, the day of, and day after Pemetrexed (Alimta)
21-day cycles
References
- Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003 Jul 15;21(14):2636-44. link to original article contains verified protocol PubMed
- Update: Manegold C, Symanowski J, Gatzemeier U, Reck M, von Pawel J, Kortsik C, Nackaerts K, Lianes P, Vogelzang NJ. Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. Ann Oncol. 2005 Jun;16(6):923-7. Epub 2005 Apr 11. link to original article PubMed
- Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, Rivière F, Janicot H, Gervais R, Locher C, Milleron B, Tran Q, Lebitasy MP, Morin F, Creveuil C, Parienti JJ, Scherpereel A; French Cooperative Thoracic Intergroup (IFCT). Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016 Apr 2;387(10026):1405-14. Epub 2015 Dec 21. Erratum in: Lancet. 2016 Apr 2;387(10026):e24. link to original article contains protocol PubMed
MVP
back to top |
MVP: Mitomycin, Vinblastine, Platinol (Cisplatin)
Regimen
Study | Evidence | Comparator | Efficacy |
Muers et al. (MS01) | Phase III | Active symptom control | Seems not superior |
Vinorelbine | Seems not superior |
Not considered a standard of care, included because it was a comparator arm.
References
- Muers MF, Stephens RJ, Fisher P, Darlison L, Higgs CM, Lowry E, Nicholson AG, O'Brien M, Peake M, Rudd R, Snee M, Steele J, Girling DJ, Nankivell M, Pugh C, Parmar MK; MS01 Trial Management Group. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet. 2008 May 17;371(9625):1685-94. link to PMC article PubMed
PCB
back to top |
PCB: Pemetrexed, Cisplatin, Bevacizumab
Regimen
Study | Evidence | Comparator | Efficacy |
Zalcman et al. 2016 (MAPS) | Phase III | PC | Seems to have superior OS |
Chemotherapy
- Pemetrexed (Alimta) 500 mg/m2 IV once on day 1
- Cisplatin (Platinol) 75 mg/m2 IV once on day 1
- Bevacizumab (Avastin) 15 mg/kg IV once on day 1
21-day cycle for up to six cycles, until progression or toxic effects
References
- Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, Rivière F, Janicot H, Gervais R, Locher C, Milleron B, Tran Q, Lebitasy MP, Morin F, Creveuil C, Parienti JJ, Scherpereel A; French Cooperative Thoracic Intergroup (IFCT). Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016 Apr 2;387(10026):1405-14. Epub 2015 Dec 21. Erratum in: Lancet. 2016 Apr 2;387(10026):e24. link to original article contains protocol PubMed
Pemetrexed (Alimta)
back to top |
Regimen
Study | Evidence |
Taylor et al. 2008 | Phase II |
Chemotherapy
- Pemetrexed (Alimta) 500 mg/m2 IV over 10 minutes once on day 1
Supportive medications
- Folic acid 350 to 600 mcg PO once per day, starting 1 to 2 weeks before pemetrexed, to continue throughout therapy and at least 3 weeks after the last dose of Pemetrexed (Alimta)
- Cyanocobalamin (Vitamin B12) 1000 mcg IM once 1 to 2 weeks before Pemetrexed (Alimta), then 1000 mcg to be given every 9 weeks thereafter while continuing on pemetrexed therapy
- Dexamethasone (Decadron) 4 mg PO BID the day before, the day of, and day after Pemetrexed (Alimta)
21-day cycles
References
- Taylor P, Castagneto B, Dark G, Marangolo M, Scagliotti GV, van Klaveren RJ, Labianca R, Serke M, Schuette W, van Meerbeeck JP, Heigener D, Liu Y, Adachi S, Blatter J, von Pawel J. Single-agent pemetrexed for chemonaïve and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program. J Thorac Oncol. 2008 Jul;3(7):764-71. link to original article contains verified protocol PubMed
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
Muers et al. (MS01) | Phase III | Active symptom control | Might have superior OS |
MVP | Seems not superior |
Note: The NCCN, Malignant Pleural Mesothelioma version 2.2012, lists the Vinorelbine (Navelbine) dosage as 25 to 30 mg/m2. No primary reference could be found for the 25 mg/m2 dosage.
Chemotherapy
- Vinorelbine (Navelbine) 30 mg/m2 IV once per week x 12 weeks, with a 2-week treatment-free gap between the 6th and 7th doses
12-week course
References
- Muers MF, Stephens RJ, Fisher P, Darlison L, Higgs CM, Lowry E, Nicholson AG, O'Brien M, Peake M, Rudd R, Snee M, Steele J, Girling DJ, Nankivell M, Pugh C, Parmar MK; MS01 Trial Management Group. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet. 2008 May 17;371(9625):1685-94. link to original article contains verified protocol PubMed
Second-line therapy
Best supportive care
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
Jassem et al. 2008 | Phase III | Pemetrexed | Seems to have inferior PFS |
No antineoplastic treatment; used as a comparator arm and here for reference purposes only.
References
- Jassem J, Ramlau R, Santoro A, Schuette W, Chemaissani A, Hong S, Blatter J, Adachi S, Hanauske A, Manegold C. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol. 2008 Apr 1;26(10):1698-704. link to original article contains verified protocol PubMed
Gemcitabine (Gemzar)
back to top |
Note: The NCCN, Malignant Pleural Mesothelioma version 2.2012, lists Gemcitabine (Gemzar) as a second-line monotherapy treatment option, but the listed reference did not provide details about its administration. No primary reference could be found for dosing of Gemcitabine (Gemzar) monotherapy in this setting, although its use is described in the first line, where it has been generally ineffective.
References
- Manegold C, Symanowski J, Gatzemeier U, Reck M, von Pawel J, Kortsik C, Nackaerts K, Lianes P, Vogelzang NJ. Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. Ann Oncol. 2005 Jun;16(6):923-7. Epub 2005 Apr 11. link to original article PubMed
Pemetrexed (Alimta)
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
Jassem et al. 2008 | Phase III | Best supportive care | Seems to have superior PFS |
Chemotherapy
- Pemetrexed (Alimta) 500 mg/m2 IV over 10 minutes once on day 1
Supportive medications
- Folic acid 350 to 1000 mcg PO once per day, starting 1 to 2 weeks before Pemetrexed (Alimta), to continue throughout therapy and at least 3 weeks after the last dose of pemetrexed
- Cyanocobalamin (Vitamin B12) 1000 mcg IM once 1 to 2 weeks before Pemetrexed (Alimta), then 1000 mcg to be given every 9 weeks thereafter while continuing on pemetrexed therapy
- Dexamethasone (Decadron) 4 mg PO BID the day before, the day of, and day after Pemetrexed (Alimta)
21-day cycle for 8 or more cycles
References
- Jassem J, Ramlau R, Santoro A, Schuette W, Chemaissani A, Hong S, Blatter J, Adachi S, Hanauske A, Manegold C. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol. 2008 Apr 1;26(10):1698-704. link to original article contains verified protocol PubMed
back to top |
Regimen
Study | Evidence |
Stebbing et al. 2008 | Phase II |
Chemotherapy
- Vinorelbine (Navelbine) 30 mg/m2 (maximum of 60 mg per dose) IV over 5 minutes once per day on days 1, 8, 15, 22, 29, 36
42-day cycles
References
- Stebbing J, Powles T, McPherson K, Shamash J, Wells P, Sheaff MT, Slater S, Rudd RM, Fennell D, Steele JP. The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma. Lung Cancer. 2009 Jan;63(1):94-7. Epub 2008 May 16. link to original article contains verified protocol PubMed
Patient resources
- TreatMesothelioma.org - "a Mesothelioma Treatment Community" with education information for patients about mesothelioma and treatment